EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential Response of Mycosis Fungoides Cells to Vorinostat

Zachary A Bordeaux, Sriya V Reddy iD, Kevin Lee, Weiying Lu, Justin Choi, Meghan Miller iD, Callie Roberts iD, Anthony Pollizzi, Shawn G Kwatra iD, Madan M Kwatra

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Zachary A Bordeaux und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL) and is characterized by epidermotrophism of malignant CD4+ T-lymphocytes. When MF advances to a recurrent stage, patients require treatment with systemic therapies such as vorinostat, a histone deacetylase inhibitor. While vorinostat has been shown to exhibit anti-tumor activity in MF, its exact molecular mechanism has yet to be fully discerned. In the present study, we examined the transcriptomic and proteomic profiles of vorinostat treatment in two MF cell lines, Myla 2059 and HH. We find that vorinostat downregulates CTLA-4, CXCR4, and CCR7 in both cell lines, but its effect on several key pathways differs between the two MF cell lines. For example, vorinostat upregulates CCL5, CCR5, and CXCL10 expression in Myla cells but downregulates CCL5 and CXCL10 expression in HH cells. Furthermore, vorinostat upregulates IFN-γ and IL-23 signaling and downregulates IL-6, IL-7, and IL-15 signaling in Myla cells but does not affect these pathways in HH cells. Although Myla and HH represent established MF cell lines, their distinct tumor origin from separate patients demonstrates that inherent phenotypic variations within the disease persist, underscoring the importance of using a variety of MF cells in the preclinical development of MF therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycosis FungoidesLymphoma, T-Cell, CutaneousSkin NeoplasmsHumansVorinostatProteomics

Stichwörter der Autor:innen

cutaneous T-cell lymphoma (CTCL)histone deacetylase inhibitormycosis fungoides (MF)vorinostat

Substanzen

Vorinostat

Autor:innen und Institutionen

  • Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.

ORCID-Profile: Sriya V Reddy, Meghan Miller, Callie Roberts, Shawn G Kwatra

Zitieren

APA

Bordeaux, Z. A., Reddy, S. V., Lee, K., Lu, W., Choi, J., Miller, M., Roberts, C., Pollizzi, A., Kwatra, S. G., & Kwatra, M. M. (2023). Differential Response of Mycosis Fungoides Cells to Vorinostat. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098075

Vancouver

Bordeaux ZA, Reddy SV, Lee K, Lu W, Choi J, Miller M, et al. Differential Response of Mycosis Fungoides Cells to Vorinostat. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098075

BibTeX
@article{Bordeaux2023,
  author = {Bordeaux, Zachary A and Reddy, Sriya V and Lee, Kevin and Lu, Weiying and Choi, Justin and Miller, Meghan and Roberts, Callie and Pollizzi, Anthony and Kwatra, Shawn G and Kwatra, Madan M},
  title = {Differential Response of Mycosis Fungoides Cells to Vorinostat},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098075}
}
Kostenlos starten →